Efficacy and Safety of Rivaroxaban Versus Enoxaparin in Prevention of Recurrence of Venous Thrombo-Embolism Events in Cancer Patients: A Meta-Analysis.

Clin Appl Thromb Hemost · 2024 · PMC11179539 · PMID 38870350

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Our analysis also consolidates these findings, where two-thirds of the included studies reported VTE occurrence following the initiation of anti-coagulant therapy; with rivaroxaban showing a decreasing trend in association with VTE occurrence versus enoxaparin.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.